216 related articles for article (PubMed ID: 20467359)
1. Pathophysiology of Graves' ophthalmopathy.
Stiebel-Kalish H; Robenshtok E; Gaton DD
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():178-81. PubMed ID: 20467359
[TBL] [Abstract][Full Text] [Related]
2. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
3. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy.
Feldon SE; Park DJ; O'Loughlin CW; Nguyen VT; Landskroner-Eiger S; Chang D; Thatcher TH; Phipps RP
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3913-21. PubMed ID: 16249464
[TBL] [Abstract][Full Text] [Related]
4. Thyroid-associated eye disease.
Heufelder AE; Joba W
Strabismus; 2000 Jun; 8(2):101-11. PubMed ID: 10980691
[TBL] [Abstract][Full Text] [Related]
5. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
6. Precipitation of the thyrotropin receptor and identification of thyroid autoantigens using Graves' disease immunoglobulins.
Heyma P; Harrison LC
J Clin Invest; 1984 Sep; 74(3):1090-7. PubMed ID: 6088581
[TBL] [Abstract][Full Text] [Related]
7. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
9. The cardiac calsequestrin gene (CASQ2) is up-regulated in the thyroid in patients with Graves' ophthalmopathy--support for a role of autoimmunity against calsequestrin as the triggering event.
Wescombe L; Lahooti H; Gopinath B; Wall JR
Clin Endocrinol (Oxf); 2010 Oct; 73(4):522-8. PubMed ID: 20039900
[TBL] [Abstract][Full Text] [Related]
10. Role of macrophage infiltration in the orbital fat of patients with Graves' ophthalmopathy.
Chen MH; Chen MH; Liao SL; Chang TC; Chuang LM
Clin Endocrinol (Oxf); 2008 Aug; 69(2):332-7. PubMed ID: 18284633
[TBL] [Abstract][Full Text] [Related]
11. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy.
Nguyen B; Gopinath B; Tani J; Wescombe L; Wall JR
Autoimmunity; 2008 Aug; 41(5):372-6. PubMed ID: 18568642
[TBL] [Abstract][Full Text] [Related]
13. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.
Cozma I; Zhang L; Uddin J; Lane C; Rees A; Ludgate M
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1630-5. PubMed ID: 17848636
[TBL] [Abstract][Full Text] [Related]
14. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.
Eckstein A; Esser J; Mann K; Schott M
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():198-203. PubMed ID: 20467363
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.
Moshkelgosha S; So PW; Deasy N; Diaz-Cano S; Banga JP
Endocrinology; 2013 Sep; 154(9):3008-15. PubMed ID: 23900776
[TBL] [Abstract][Full Text] [Related]
17. Ethnic differences in the clinical presentation of Graves' ophthalmopathy.
Chng CL; Seah LL; Khoo DH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):249-58. PubMed ID: 22632362
[TBL] [Abstract][Full Text] [Related]
18. The relationship between anti-human eye muscle antibodies and thyroid function, anti-TSH receptor antibodies and eye symptoms in Graves' ophthalmopathy.
Molnár I; Balázs C
Wien Klin Wochenschr; 1992; 104(24):744-7. PubMed ID: 1363165
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of Graves' ophthalmopathy].
Heufelder AE
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():35-9. PubMed ID: 10355048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
